menu
    • menu
    [{"orgOrder":0,"company":"Allermi","sponsor":"Lucas Venture Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Financing","leadProduct":"Triamcinolone","moa":"Ach receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Lucas Venture Group","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Lucas Venture Group"},{"orgOrder":0,"company":"Allermi","sponsor":"Nelstone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Financing","leadProduct":"Triamcinolone","moa":"Ach receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Nelstone Ventures","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Nelstone Ventures"},{"orgOrder":0,"company":"Allermi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Ach receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Allermi","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Allermi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Allermi \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Aristocort Tablets

    Menu

    Aristocort Tablets

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Allermi

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Allermi

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Nelstone Ventures

                            Deal Size : $3.5 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Allermi Secures $3.5M in Seed Funding to Meet Growing Demand for Customized Approach to Allergy Symptoms

                            Details : The seed funding will support massive national expansion of world’s first customized multi-ingredient nasal Allermi Super Spray, build and scale business, marketing and product operations; and enlarge marketing channels to meet the growing demand.

                            Product Name : Allermi Super Spray

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            March 16, 2023

                            Lead Product(s) : Triamcinolone

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Nelstone Ventures

                            Deal Size : $3.5 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Allermi

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Allermi

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Lucas Venture Group

                            Deal Size : $1.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Allermi Launches First and Only Customized, Multi-Ingredient Nasal Spray to Offer Relief to Millions of Allerg...

                            Details : Allermi Super Spray that combines up to four active ingredients into one bottle. It targets a variety of symptoms, while being safe to take every day.

                            Product Name : Allermi Super Spray

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            August 09, 2022

                            Lead Product(s) : Triamcinolone

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Lucas Venture Group

                            Deal Size : $1.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Allermi

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Allermi

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Triamcinolone

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Allermi Launches First and Only Customized, Multi-Ingredient Nasal Spray to Offer Relief to Millions of Allerg...

                            Details : Allermi Super Spray that combines up to four active ingredients into one bottle. It targets a variety of symptoms, while being safe to take every day.

                            Product Name : Allermi Super Spray

                            Product Type : Steroid

                            Upfront Cash : Inapplicable

                            August 09, 2022

                            Lead Product(s) : Triamcinolone

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth